NCT05432882View on ClinicalTrials.gov

CD19/22 Bi-specific CAR-T Cell Therapy

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
B Cell Malignancies
Interventions
BIOLOGICAL

bi-4SCAR CD19/22 T cells

Infusion of bi-4SCAR CD19/22 T cells at 10\^6 cells/kg body weight via IV

Trial Locations (1)

518000

RECRUITING

Shenzhen Geno-immune Medical Institute, Shenzhen

All Listed Sponsors
lead

Shenzhen Geno-Immune Medical Institute

OTHER